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Background
The absolute risk of angiotensin-converting enzyme (ACE)
inhibitor angioedema is 0.3% [1]. The mechanism is felt to
be accumulation of bradykinin. The current treatment is
discontinuation of ACE-I inhibitor, and intubation if
necessary. Icatibant is a bradykinin receptor antagonist,
useful in treating hereditary angioedema [2]. We present a
patient from a Canadian center who had ACE-inhibitor
induced angioedema requiring intubation who did not
respond to epinephrine or C1 esterase inhibitor concen-
trate, then later responded favorably to Icatibant.
Case presentation
We present a case of a 76 year old male with hypertension,
type II diabetes, no allergies, who was seen in the ER with
acute new-onset tongue and facial swelling. He had a virus
2 weeks prior. His medications included quinapril, simvas-
tatin, repaglinide, metformin, pioglitazone, and aspirin.
He had a swollen tongue, oral cavity, neck and was
unable to swallow. There was no urticaria. He was given
diphenhydramine 50mg IV, methylprednisolone 125mg
IV, epinephrine 0.3mg IM, and ranitidine 50mg IV.
Swelling progressed and he was intubated.
Over the next 24 hours, he received methylpredniso-
lone 80mg every 8 hours, ranitidine 50mg every 8 hours,
diphenhydramine 50mg every 6 hours, two doses of C1
esterase inhibitor concentrate, 1500 units IV followed by
1000 units. Quinipril was discontinued. Computed
tomography of the neck showed no abscess.
Over the next 2 days there was minimal improvement.
Therefore, on hospital day 3, he received 3 doses of Icati-
bant 30 mg over 24 hours. Improvement was noted, and
by the next day, he was extubated. Following overnight
monitoring, he was transferred to the medicine ward.
There was no recurrence and he was discharged. C1
esterase inhibitor level and function was normal (drawn
prior to infusion).
At his two month follow up he remained asympto-
matic. ACE inhibitors and Angiotensin Receptor Blockers
are avoided. He was diagnosed with myelodysplastic syn-
drome following work up for anemia noted on admission.
There have been published reports outside of Canada
describing the use of Icatibant in ACE-inhibitor induced
angioedema [3].
Icatibant is not indicated in Canada for ACE-inhibitor
induced angioedema. However, it may need to be con-
sidered in severe cases.
Conclusion
Icatibant may be helpful in ACE-inhibitor induced angioe-
dema when the patient has not responded to the disconti-
nuation of the ACE inhibitor and alternative therapies.
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